Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity

Stopped early · Phase 4 · Has a placebo group

Conditions studied: Retinopathy of Prematurity, Retinal Detachment, Blindness

In brief

The purpose of this study is to test whether ACULAR, a nonsteroidal anti-inflammatory eye drop medication, can prevent the development of retinopathy of prematurity (ROP) and/ or decrease its severity.In this study ACULAR will be compared to a placebo (artificial tear). The hypothesis would be that ACULAR treatment will decrease the incidence of moderate to severe ROP (grade II and above)by 50%.

Key facts

Study ID

NCT00634972

Run by

University of South Alabama

People needed

83

Starts

2005-11-01

Expected to finish

2008-08-01

Last updated by the study team

2020-12-08

Who can join

Age: 0 and older, up to 0. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• All preterm infants of gestational age less or equal to 28 weeks completed gestational age and 10 to 15 days of postnatal age admitted to our regional NICU

Where it is running

• Division of Neonatology, Children's & Women's Hospital, University of South Alabama — Mobile, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.